Darshan Kulkarni’s Post

Join me at Dynamic Global Events (DGE)'s 5th Clinical Trial Agreements on August 22nd at 11:45! We'll delve into the pivotal role CTAs play in mergers and acquisitions, especially in pharma and biotech. Learn about key M&A due diligence, the transformative potential of AI in CTAs, and the importance of standard templates for streamlining clinical trials. Register now. Link in comments. #clinicaltrials #clinicaltrialagreements #mergersandacquisitions #DGEvents

Join me at Dynamic Global Events (DGE)'s 5th Clinical Trial Agreements on August 22nd at 11:45! We'll delve into the pivotal role CTAs play in mergers and acquisitions, especially in pharma and biotech. Learn about key M&A due diligence, the transformative potential of AI in CTAs, and the importance of standard templates for streamlining clinical trials. Click below to register now. #clinicaltrials #clinicaltrialagreements #mergersandacquisitions #DGEvents

Mark your calendar! I’ll be speaking at DGE’s 5th Clinical Trial Agreements on August 22nd at 11:45. Learn about the critical role of CTAs in M&As, AI advancements, M&A due diligence, and the power of standard templates. Click below to register now. #clinicaltrialcompliance #MandA #klf

Drug Hunter 2023 M&A Review: Part 2 - Small Molecule-Focused Deals 20-11 | https://lnkd.in/gSPNP-A5 Drug Hunter has sifted through news articles, press releases, financial disclosures, SEC filings, and more to bring you a roundup of 2023’s biggest mergers and acquisitions (M&A) in the drug discovery world. Following our open-access industry overview, in part 2 of this 4-part series, we bring you the small molecule-focused deals opening checkbooks in 2023, ranked 20-11 by value. From Novo Nordisk’s double bet on dominating the weight loss market through their acquisitions of Inversago Pharma and Embark biotech, to Eli Lilly and Company positioning themselves as Novartis' main competition in the radioligand space with their deal to buy POINT biopharma, read our in-depth background and analysis in this article. Also included is our patent analysis of the undisclosed structures of assets driving the purchases of companies such as Albireo Pharma by Ipsen and Mitokinin by AbbVie. In the coming weeks, we will be providing similarly detailed coverage and analysis of the top small molecule-focused deals (part 3) as well as those centered around biologics-based assets (part 4). Read it on Drug Hunter | https://lnkd.in/gSPNP-A5

In recent years, challenges securing capital among #lifesciences companies have benefited the more prominent players in the industry who are hoping to acquire smaller companies. According to Curavit's CEO, Joel Morse, “The big players…have the capital to make investments in innovative companies that have worked hard and, in some cases, gotten over the line with the FDA but need market access and more health economic research.” Hear more from Joel and other experts in this LifeSciencesIntelligence article discussing the primary goals of mergers and acquisitions in the lifes ciences industry. #heor #clinicalresearch #dcts #dtx https://lnkd.in/ge9jcgY4

Exciting news for the pharma industry! A recent report predicts an uptick in mergers and acquisitions in 2024, continuing the trend from this year. Read more about the forecasted growth. #PharmaNews #MergersAndAcquisitions

⚖️Ilumina/Grail sheds light into the use (or abuse) of art.22 of the EUMR. ❓The one-million dollar question that we all have in mind today: Will the Commission and National Competition authorities revamp their merger thresholds to be able to review innovation-driven mergers? https://lnkd.in/eYg9dBP7 #competitionlaw #innovation #mergercontrol

Exciting news for the pharma industry! A recent report predicts an uptick in mergers and acquisitions in 2024, continuing the trend from this year. Read more about the forecasted growth. #PharmaNews #MergersAndAcquisitions

Exciting news for the pharma industry! A recent report predicts an uptick in mergers and acquisitions in 2024, continuing the trend from this year. Read more about the forecasted growth. #PharmaNews #MergersAndAcquisitions

Exciting news for the pharma industry! A recent report predicts an uptick in mergers and acquisitions in 2024, continuing the trend from this year. Read more about the forecasted growth. #PharmaNews #MergersAndAcquisitions